|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Inventories, net (Note 7) | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Value added tax receivable, net (Note 7) | ||||||||||||||||||||
| Prepaid expenses and other assets (Note 5) | ||||||||||||||||||||
| Current assets held for sale (Note 4) | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net (Note 6) | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Right-of-use assets | ||||||||||||||||||||
| Right-of-use assets (Note 9) | ||||||||||||||||||||
| Assets held for sale (Note 3) | ||||||||||||||||||||
| Assets held for sale (Note 4) | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable and other accrued liabilities (Note 8) | ||||||||||||||||||||
| Accounts payable and other accrued liabilities (Note 5 & 7) | ||||||||||||||||||||
| Deferred revenue (Note 9) | ||||||||||||||||||||
| Deferred revenue (Note 3) | ||||||||||||||||||||
| Other current liabilities (Note 11) | ||||||||||||||||||||
| Current liabilities held for sale (Note 4) | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Asset retirement and reclamation liabilities (Note 10) | ||||||||||||||||||||
| Other long-term liabilities (Note 11) | ||||||||||||||||||||
| Liabilities held for sale (Note 4) | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity (Note 10) | ||||||||||||||||||||
| Common stock, $.01 par value, 100,000,000 shares authorized; 18,893,048 and 15,053,048 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
